Perioperative treatment and biomarker analysis of LP002, an anti-PD-L1 antibody, plus chemotherapy in resectable gastric and gastroesophageal junction cancer.

Jia-Lin TangBo ZhangJian-Ping XuLing QiDao Xin Lin WangBing-Zhi WangYan-Tao TianYong LiJing Huang

Published in: Cancer medicine (2022)

LP002 plus cisplatin and 5-fluorouracil are safe in patients with gastric or GEJ cancer, and patient selection via appropriate biomarkers is needed in the future.

Keyphrases

papillary thyroid
squamous cell
locally advanced
patients undergoing
squamous cell carcinoma
lymph node metastasis
radiation therapy
current status
young adults
acute kidney injury
rectal cancer